Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Peptides play important roles in human physiology. They present as intact peptides or can arise from protein degradation. Regardless of the source, peptidomics—the characterization of intact peptides in a biological sample—is fast emerging as an approach to uncover another layer in human health and disease.
Paradigm4 announces the general availability of flexFS, a hyperscale file system designed for AI/ML and large file data workloads, providing unparalleled throughput at 50% lower cost
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
